{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:42:55Z","timestamp":1782963775612,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Foamix Pharmaceuticals, Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40257-017-0339-0","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T08:44:23Z","timestamp":1517561063000},"page":"427-436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A Phase II, Randomized, Double-Blind Clinical Study Evaluating the Safety, Tolerability, and Efficacy of a Topical Minocycline Foam, FMX103, for the Treatment of Facial Papulopustular Rosacea"],"prefix":"10.1007","volume":"19","clinical-trial-number":[{"clinical-trial-number":"nct02601963","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ulrich","family":"Mrowietz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal Hetzroni","family":"Kedem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Keynan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meir","family":"Eini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dov","family":"Tamarkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Rom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Shirvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"issue":"5","key":"339_CR1","first-page":"234","volume":"92","author":"JQ Del Rosso","year":"2013","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield L, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92(5):234\u201340.","journal-title":"Cutis"},{"issue":"3","key":"339_CR2","first-page":"187","volume":"92","author":"LK Oge","year":"2015","unstructured":"Oge LK, Muncie HL, Phillips-Savoy AR. Rosacea: diagnosis and treatment. Am Fam Physician. 2015;92(3):187\u201396.","journal-title":"Am Fam Physician"},{"issue":"6","key":"339_CR3","first-page":"348","volume":"6","author":"TT Huynh","year":"2013","unstructured":"Huynh TT. Burden of disease: the psychosocial impact of rosacea on a patient\u2019s quality of life. Am Health Drug Benefits. 2013;6(6):348\u201354.","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"339_CR4","first-page":"18","volume":"93","author":"JQ Del Rosso","year":"2014","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis. 2014;93(1):18\u201328.","journal-title":"Cutis"},{"issue":"3","key":"339_CR5","first-page":"134","volume":"93","author":"JQ Del Rosso","year":"2014","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis. 2014;93(3):134\u20138.","journal-title":"Cutis"},{"issue":"2","key":"339_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bph.12139","volume":"169","author":"N Garrido-Mesa","year":"2013","unstructured":"Garrido-Mesa N, Zarzuelo A, Galvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169(2):337\u201352. https:\/\/doi.org\/10.1111\/bph.12139.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"339_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2009.04.007","volume":"55","author":"K Yamasaki","year":"2009","unstructured":"Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009;55(2):77\u201381. https:\/\/doi.org\/10.1016\/j.jdermsci.2009.04.007.","journal-title":"J Dermatol Sci"},{"key":"339_CR8","doi-asserted-by":"publisher","first-page":"CD003262","DOI":"10.1002\/14651858.cd003262.pub5","volume":"4","author":"EJ van Zuuren","year":"2015","unstructured":"van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. Cochrane Database Syst Rev. 2015;4:CD003262. https:\/\/doi.org\/10.1002\/14651858.cd003262.pub5.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"339_CR9","first-page":"1022","volume":"16","author":"TM Jones","year":"2017","unstructured":"Jones TM, Ellman H, deVries T. Pharmacokinetic comparison of once-daily topical minocycline foam 4% vs oral minocycline for moderate-to-severe acne. J Drugs Dermatol. 2017;16(10):1022\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"339_CR10","first-page":"1238","volume":"15","author":"S Chamny","year":"2016","unstructured":"Chamny S, Miron D, Lumelsky N, Shalev H, Gazal E, Keynan R, et al. Topical minocycline foam for the treatment of impetigo in children: results of a randomized, double-blind, phase 2 study. J Drugs Dermatol. 2016;15(10):1238\u201343.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"339_CR11","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jaad.2015.09.065","volume":"74","author":"A Shemer","year":"2016","unstructured":"Shemer A, Shiri J, Mashiah J, Farhi R, Gupta AK. Topical minocycline foam for moderate to severe acne vulgaris: phase 2 randomized double-blind, vehicle-controlled study results. J Am Acad Dermatol. 2016;74(6):1251\u20132. https:\/\/doi.org\/10.1016\/j.jaad.2015.09.065.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"339_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaad.2007.01.048","volume":"57","author":"K Nicholson","year":"2007","unstructured":"Nicholson K, Abramova L, Chren MM, Yeung J, Chon SY, Chen SC. A pilot quality-of-life instrument for acne rosacea. J Am Acad Dermatol. 2007;57(2):213\u201321. https:\/\/doi.org\/10.1016\/j.jaad.2007.01.048.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"339_CR13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1517\/17425247.3.6.799","volume":"3","author":"D Tamarkin","year":"2006","unstructured":"Tamarkin D, Friedman D, Shemer A. Emollient foam in topical drug delivery. Expert Opin Drug Deliv. 2006;3(6):799\u2013807. https:\/\/doi.org\/10.1517\/17425247.3.6.799.","journal-title":"Expert Opin Drug Deliv"},{"issue":"6","key":"339_CR14","first-page":"277","volume":"92","author":"JQ Del Rosso","year":"2013","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield L, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis. 2013;92(6):277\u201384.","journal-title":"Cutis"},{"issue":"2","key":"339_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/bjd.15173","volume":"176","author":"M Schaller","year":"2017","unstructured":"Schaller M, Almeida L, Bewley A, Cribier B, Dlova N, Kautz G, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):465\u201371. https:\/\/doi.org\/10.1111\/bjd.15173.","journal-title":"Br J Dermatol"},{"issue":"6","key":"339_CR16","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/bjd.15155","volume":"176","author":"MM van der Linden","year":"2017","unstructured":"van der Linden MM, van Ratingen AR, van Rappard DC, Nieuwenburg SA, Spuls PI. DOMINO, doxycycline 40\u00a0mg vs minocycline 100\u00a0mg in the treatment of rosacea: a randomised, single blinded, non-inferiority trial, comparing efficacy and safety. Br J Dermatol. 2017;176(6):1465\u201374. https:\/\/doi.org\/10.1111\/bjd.15155.","journal-title":"Br J Dermatol"},{"key":"339_CR17","unstructured":"ORACEA [package insert]. Fort Worth, Tex: Galderma; December 2014."},{"issue":"9","key":"339_CR18","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","volume":"27","author":"K Smith","year":"2005","unstructured":"Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27(9):1329\u201342. https:\/\/doi.org\/10.1016\/j.clinthera.2005.09.005.","journal-title":"Clin Ther"},{"issue":"3","key":"339_CR19","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S1473-3099(15)00527-7","volume":"16","author":"TR Walsh","year":"2016","unstructured":"Walsh TR, Efthimiou J, Dreno B. Systematic review of antibiotic resistance in acne: an increasing topical and oral threat. Lancet Infect Dis. 2016;16(3):e23\u201333. https:\/\/doi.org\/10.1016\/S1473-3099(15)00527-7.","journal-title":"Lancet Infect Dis."},{"issue":"8","key":"339_CR20","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1001\/jamadermatol.2017.1297","volume":"153","author":"BL Adler","year":"2017","unstructured":"Adler BL, Kornmehl H, Armstrong AW. Antibiotic resistance in acne treatment. JAMA Dermatol. 2017;153(8):810\u20131. https:\/\/doi.org\/10.1001\/jamadermatol.2017.1297.","journal-title":"JAMA Dermatol."},{"issue":"5","key":"339_CR21","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","volume":"74","author":"AL Zaenglein","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945\u201373. https:\/\/doi.org\/10.1016\/j.jaad.2015.12.037.","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"339_CR22","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1365-4632.2011.05403.x","volume":"52","author":"N Mendoza","year":"2013","unstructured":"Mendoza N, Hernandez PO, Tyring SK, Haitz KA, Motta A. Antimicrobial susceptibility of Propionibacterium acnes isolates from acne patients in Colombia. Int J Dermatol. 2013;52(6):688\u201392. https:\/\/doi.org\/10.1111\/j.1365-4632.2011.05403.x.","journal-title":"Int J Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-017-0339-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-017-0339-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-017-0339-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:37:58Z","timestamp":1628617078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-017-0339-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["339"],"URL":"https:\/\/doi.org\/10.1007\/s40257-017-0339-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,2]]},"assertion":[{"value":"2 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tal Hetzroni Kedem is an employee of, and has stocks in, Foamix Pharmaceuticals and has a patent or intellectual property interest to disclose at Foamix Pharmaceuticals. Rita Keynan is an employee of, and has a few patents written for, Foamix Pharmaceuticals. Dov Tamarkin and Mitchell Shirvan are employees of Foamix Pharmaceuticals. Meir Eini receives stock options and royalties from Foamix Pharmaceuticals. Dror Rom was a consultant of the Clinical Research Organization involved in the analysis of the clinical trial. The study was conducted in accordance with Good Clinical Practice.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Ulrich Mrowietz has no conflicts of interest that are directly relevant to the content of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}